Medicare Part D Coverage For Obesity Drugs Urged By House Appropriations Panel

In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.

House Appropriators Point To the Health and Equity Benefits Of Obesity Drugs • Source: Shutterstock

More from Market Access

More from Pink Sheet